Won-Seok Lee

Won-Seok Lee

Auto-generated profile, based on publicly available information

Won-Seok Lee

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
EBEmma L. Bunting
Emma L. Bunting
JDJasmine Donaldson
Jasmine Donaldson
SCSarah Ann Cumming
Sarah Ann Cumming
JOJessica Olive
Jessica Olive
EBElizabeth Broom
Elizabeth Broom
STSarah J. Tabrizi
Sarah J. Tabrizi
Expanded CAG alleles in the huntingtin ( HTT ) gene that cause the neurodegenerative disorder Huntington’s disease (HD) are genetically unstable and continue to expand somatically throughout life, driving HD onset and progression. MSH3, a DNA mismatch repair protein, modifies HD onset and progression by driving this somatic CAG repeat expansion process. MSH3 is relatively tolerant of loss-of-function variation in humans, making it a potential therapeutic target. Here, we show that an MSH3 -targeting antisense oligonucleotide (ASO) effectively engaged with its RNA target in induced pluripotent stem cell (iPSC)–derived striatal neurons obtained from a patient with HD carrying 125 HTT CAG repeats (the 125 CAG iPSC line). ASO treatment led to a dose-dependent reduction of MSH3 and subsequent stalling of CAG repeat expansion in these striatal neurons. Bulk RNA sequencing revealed a safe profile for MSH3 reduction, even when reduced by >95%. Maximal knockdown of MSH3 also effectively slowed CAG repeat expansion in striatal neurons with an otherwise accelerated expansion rate, derived from the 125 CAG iPSC line where FAN1 was knocked out by CRISPR-Cas9 editing. Last, we created a knock-in mouse model expressing the human MSH3 gene and demonstrated effective in vivo reduction in human MSH3 after ASO treatment. Our study shows that ASO-mediated MSH3 reduction can prevent HTT CAG repeat expansion in HD 125 CAG iPSC–derived striatal neurons, highlighting the therapeutic potential of this approach.

1 October 2012 in Biomaterials
Verified
Journal Article
Closed access
TPTae-Eun Park
Tae-Eun Park
BKBitna Kang
Bitna Kang
YKYou-Kyoung Kim
You-Kyoung Kim
QZQiankun Zhang
Qiankun Zhang
WLWon-Seok Lee
Won-Seok Lee
CCChong-Su Cho
Chong-Su Cho

1 April 2014 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
WLWon-Seok Lee
Won-Seok Lee
YKYou-Kyoung Kim
You-Kyoung Kim
QZQiankun Zhang
Qiankun Zhang
TPTae-Eun Park
Tae-Eun Park
SKSang-Kee Kang
Sang-Kee Kang
YCYun Jaie Choi
Yun Jaie Choi

11 March 2021 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
WLWon‐Seok Lee
Won‐Seok Lee
LLLaura Lavery
Laura Lavery
MRMaxime W C Rousseaux
Maxime W C Rousseaux
EREric B Rutledge
Eric B Rutledge
YJYoujin Jang
Youjin Jang
HZHuda Y Zoghbi
Huda Y Zoghbi

2 May 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
WLWon-Seok Lee
Won-Seok Lee
IAIsmael Al-Ramahi
Ismael Al-Ramahi
HJHyun-Hwan Jeong
Hyun-Hwan Jeong
YJYoujin Jang
Youjin Jang
TLTao Lin
Tao Lin
HZHuda Y. Zoghbi
Huda Y. Zoghbi
Many neurodegenerative disorders are caused by abnormal accumulation of misfolded proteins. In spinocerebellar ataxia type 1 (SCA1), accumulation of polyglutamine-expanded (polyQ-expanded) ataxin-1 (ATXN1) causes neuronal toxicity. Lowering total ATXN1, especially the polyQ-expanded form, alleviates disease phenotypes in mice, but the molecular mechanism by which the mutant ATXN1 is specifically modulated is not understood. Here, we identified 22 mutant ATXN1 regulators by performing a cross-species screen of 7787 and 2144 genes in human cells and Drosophila eyes, respectively. Among them, transglutaminase 5 (TG5) preferentially regulated mutant ATXN1 over the WT protein. TG enzymes catalyzed cross-linking of ATXN1 in a polyQ-length–dependent manner, thereby preferentially modulating mutant ATXN1 stability and oligomerization. Perturbing Tg in Drosophila SCA1 models modulated mutant ATXN1 toxicity. Moreover, TG5 was enriched in the nuclei of SCA1-affected neurons and colocalized with nuclear ATXN1 inclusions in brain tissue from patients with SCA1. Our work provides a molecular insight into SCA1 pathogenesis and an opportunity for allele-specific targeting for neurodegenerative disorders.

11 December 2025 in bioRxiv
Verified
Preprint
Open access
SKSeva Kashin
Seva Kashin
WLWon-Seok Lee
Won-Seok Lee
TMTara M. McDonald
Tara M. McDonald
KMKiely Morris
Kiely Morris
RHRobert E. Handsaker
Robert E. Handsaker
SMSteven A. McCarroll
Steven A. McCarroll
Huntington’s disease (HD) affects the neocortex and striatum with different timing, severity, and gene-expression changes. These pathologies have long been proposed to involve different pathogenic mechanisms, with one brain area’s degeneration leading to the other’s. Striatal neurons degenerate in HD as their huntingtin ( HTT ) CAG-repeat tracts expand somatically beyond 150 CAGs. Here we find that cortical pyramidal neurons in HD undergo biological changes analogous to those in striatal neurons – the same sequence of pathological phases, with toxicity also commencing at ∼150 CAGs yet then changing their gene expression in distinct ways. Pyramidal neurons’ precise molecular identities, rather than their areal or laminar locations, appeared to determine the extent of this somatic DNA-repeat expansion, which varied up to 20-fold among pyramidal neuron subtypes. Cortical and striatal neurons also shared a key pathological feature: nuclear inclusions of aggregated HTT protein in those nuclei with expansions well beyond 150 CAGs.